News headlines about Vermillion (NASDAQ:VRML) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Vermillion earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the company an impact score of 43.0973288282928 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

VRML has been the topic of a number of research reports. ValuEngine upgraded shares of Vermillion from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $1.75 target price (down from $2.50) on shares of Vermillion in a report on Wednesday, August 30th.

Vermillion (NASDAQ:VRML) traded up 1.48% during midday trading on Thursday, hitting $1.37. 31,952 shares of the stock were exchanged. Vermillion has a one year low of $0.76 and a one year high of $2.85. The company has a 50 day moving average price of $1.40 and a 200 day moving average price of $1.81. The firm’s market capitalization is $76.94 million.

Vermillion (NASDAQ:VRML) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Vermillion had a negative net margin of 372.05% and a negative return on equity of 215.26%. The business had revenue of $0.90 million for the quarter. Equities analysts anticipate that Vermillion will post ($0.16) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Vermillion (VRML) Share Price” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at

Vermillion Company Profile

Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.

Insider Buying and Selling by Quarter for Vermillion (NASDAQ:VRML)

Receive News & Stock Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related stocks with our FREE daily email newsletter.